Combination drug treatment before bladder cancer surgery
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests two drugs (RC48 and toripalimab) given before bladder cancer surgery for patients who cannot take the standard chemotherapy due to kidney problems or other reasons. The goal is to see if this combination can shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You cannot take the standard chemotherapy (cisplatin) because of kidney problems, hearing loss, nerve damage, or other reasons, or you choose not to.
- Your bladder cancer has not spread beyond the bladder and you are able to have surgery (removal of the bladder).
- Your tumor has a certain level of a protein called HER2 (at least 1+ on testing).
- You are willing to use effective birth control during the study (if you or your partner could become pregnant).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of two drugs (disitamab vedotin and toripalimab) for people with muscle-invasive bladder cancer that has not spread. The goal is to see if this treatment can shrink the tumor before surgery. You may qualify if your tumor has a certain level of a protein called HER2.
This study tests a new combination of an antibody-drug conjugate (a targeted therapy) with an immunotherapy drug, plus allergy and vitamin B12 medications, for advanced bladder cancer. It aims to see if this combo is safe and effective for people whose tumors have a certain marker called HER2.
This trial tests a combination of two drugs, disitamab vedotin and ivonescimab, for people with muscle-invasive bladder cancer who cannot receive standard chemotherapy with cisplatin. The goal is to see if this treatment is safe and effective before surgery.
This trial tests a new combination of two medications—one that targets HER2 on cancer cells and one that boosts your immune system—given directly into the bladder. It is for people with high-risk bladder cancer that hasn't spread into the muscle, and who haven't had BCG therapy or for whom BCG didn't work.
This study tests whether a combination of two drugs can treat bladder cancer without needing to remove the bladder. It is for people whose cancer has not spread beyond the bladder and who prefer to avoid surgery.
This trial studies giving toripalimab (an immunotherapy) together with gemcitabine and cisplatin before bladder surgery. It aims to shrink locally advanced bladder cancer and make surgery more effective by using the immune system and chemotherapy together.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.